Wellstat Therapeutics Corporation

Pro-Neuron, Inc.

Other

Wellstat Biologics Corporation

Igen International, Inc.

Filligent Limited

Defined Diagnostics, LLC

Sentiens, LLC

Pdl Biopharma, Inc.

Innonix Technologies, Incorporated

Wellstat Therapertics Corporation

Wellstat Therapeutics Coporation

Wellstat Therapeutics Orporation

Lesser, Craig

Reid W. Von Borstel

Reid W Von Borstel

Shalini Sharma

Michael K Bamat

Kirvin L Hodge

Stephen D Wolpe

Bradley M Hiltbrand

Craig Lesser

Fedor Evgenievich Romantsev

Robert Michael Lorence

David M Simpson

Michael Scot Roberts

William S Groene

Harvey Rabin

Albert C Lee

James Dennen O'Neil

Julian Reading

Paul Hu

Shyam Shirali

James C Butler

Xiaofen Huang

George B Sigal

John H Kenten

Mark T Martin

Richard J Massey

Neal George Stewart

Rodger G Smith

Balreddy Kamireddy

Richard C Titmas

Jeffrey A Heroux

Andrew D Napper

Richard O Williams

Ramachandran Arudchandran

Jan M Casadei

Dennis Bryan Zerby

Ming Lu

Rui Li

Joel A Saydoff

Dacey J Ryan

Lok Yuen Lo

Francis Chi Nan Lau

Craig A Lesser

Inna S Timokhina

John Siverling

Dennis Tan

Robert J Kaufman

Jeffrey Allan Miller

Irena Tsyrlova

Ramchandran Arudchandran

Lana Hoang Do

Nureddin Aman

Tai Wai Kung

Fawn Petty

Jiong Pei

James Dennen O'neil

Stephen Wolpe

Neal G Stewart

The disclosure relates generally to methods of detecting and quantifying methotrexate (MTX) in a sample. The methods disclosed herein decrease cross-reactivity and improve sensitivity of the detection.

Compounds and methods for the detection of methotrexate

Amine compounds having activity against inflammation, fungi, unicellular parasitic microorganisms, and cancer are described. The compounds contain a monocyclic, bicyclic, or tricyclic aromatic ring having one, two, or three ring nitrogen atoms.

Aminoquinazoline compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity

Disclosed are methods of measuring enzyme activity in a sample. The methods use disulfide-containing detection reagents with an electrochemiluminescent functional group.

Electrochemiluminescence (ECL) detection reagents and related methods for measuring enzyme activity

A device for simulating a chemosenzation of smoking includes an outer layer, a porous medium and a chemesthetic agent. The porous medium is disposed within the outer layer. The chemesthetic agent is disposed within the porous medium and activates a TRP channel.

Device and method for simulating chemosensation of smoking

Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, early-onset essential hypertension, and-induced inflammation.  In Formula I, t is 0 or 1; q is 0 or 1; and r is 0, 1 or 2. Ris hydrogen or alkyl having from 1 to 3 carbon atoms. Ris hydrogen, hydroxy, halo, alkyl having from 1 to 3 carbon atoms, alkoxy having from 1 to 3 carbon atoms, nitro, thio, alkylthio, or cyano. X is C(O) or NH(R) wherein Ris hydrogen or alkyl having from 1 to 3 carbon atoms; provided that when X is C(O), r is 0 and t is 0. A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from halo, hydroxy, methyl, ethyl, perfluoromethyl, methoxy, ethoxy, perfluoromethoxy, nitro, and amino; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of Formula I by a ring carbon; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently monosubstituted by methyl or ethyl.

Benzoic acid compounds for reducing uric acid

Amine compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity

A composition for coating a polypropylene-based fabric or polypropylene-based material for use in decreasing the transmission of human pathogens. A device such as a protective face mask made from a polypropylene-based fabric or polypropylene-based material coated with the composition.

Composition for use in decreasing the transmission of human pathogens

The present invention relates to conjugates of 5-fluorouracil, 5-fluorouracil immunogens, antibodies that bind 5-FU and/or 5-FU conjugated to another molecule, and assays for detecting, quantitating, and monitoring amounts of 5-fluorouracil in a sample such as in blood plasma.

Assays, antibodies, immunogens and compositions related to 5-FU

Stem cells are mobilized from bone marrow by administering an amount of Phe-Pro-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Ser-Asp-Lys-Pro (SEQ ID NO: 2) or Phe-Ala-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Ser-Asp-Lys-Pro (SEQ ID NO: 3) effective to mobilize the stem cells. This is useful for promoting bodily tissue regeneration in a patient in need of tissue regeneration treatment. Alternatively, the mobilized stem cells can be collected for transplant.

Stem cell mobilization and tissue repair and regeneration

Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I or a pharmaceutically acceptable salt thereof.  In Formula I m is 0, 1, 2, 3 or 4; n is 0 or 1; m+n is not more than 4; t is 0 or 1; q is 0 or 1; and r is 0, 1 or 2. Ris hydrogen, methyl or ethyl and Ris hydrogen or methyl, or Ris hydroxy and Ris hydrogen, or Ris O and Ris absent, or Rand Rtogether are &#x2014;CHCH&#x2014;. Ris hydrogen or alkyl having from 1 to 3 carbon atoms. One of Rand Ris alkyl having from 1 to 3 carbon atoms, and the other is hydrogen or alkyl having from 1 to 3 carbon atoms. Ris hydrogen, halo, alkyl having from 1 to 3 carbon atoms or alkoxy having from 1 to 3 carbon atoms. X is C(O) and r is 0 and t is 0; or X is NH(R) wherein Ris hydrogen or alkyl having from 1 to 3 carbon atoms. A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from halo, hydroxy, methyl, ethyl, perfluoromethyl, methoxy, ethoxy, and perfluoromethoxy; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of Formula I by a ring carbon; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently monosubstituted by methyl or ethyl. The uric acid-lowering effects of the Compounds of Formula I are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, and cognitive impairment.

Compounds and method for reducing uric acid

Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I or a pharmaceutically acceptable salt thereof.  In Formula I m is 0, 1, 2, 3 or 4; n is 0 or 1; t is 0 or 1; q is 0 or 1; and r is 0, 1 or 2. Ris hydrogen, O or hydroxyl. Ris hydrogen or alkyl having from 1 to 3 carbon atoms. One of Rand Ris alkyl having from 1 to 3 carbon atoms, and the other is hydrogen or alkyl having from 1 to 3 carbon atoms. Ris hydrogen, halo, alkyl having from 1 to 3 carbon atoms or alkoxy having from 1 to 3 carbon atoms. X is C(O) and r is 0 and t is 0; or X is NH(R) wherein Ris hydrogen or alkyl having from 1 to 3 carbon atoms. A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from halo, hydroxy, methyl, ethyl, perfluoromethyl, methoxy, ethoxy, and perfluoromethoxy; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of Formula I by a ring carbon; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently monosubstituted by methyl or ethyl. The uric acid-lowering effects of the Compounds of Formula I are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, and cognitive impairment.

A facial mask for use in decreasing the transmission of one or more than one human pathogen to and from a human wearer of the facial mask, the facial mask comprising a facepiece; where the facepiece comprises three or more than three layers; where one or more than one of the three or more than three layers comprises a fabric comprising one or more than one binding substance comprising one or more than one human pathogen binding group for chemically attaching the human pathogen to the binding substance; where the fabric further comprises one or more than one type of multivalent metallic ion or metallic salt; and where one or more than one of the three or more than three layers comprises a heat-moldable fabric.

Devices and methods for decreasing human pathogen transmission

A device for simulating a chemosensation of smoking includes an outer layer, a porous medium and a chemesthetic agent. The porous medium is disposed within the outer layer. The chemesthetic agent is disposed within the porous medium and activates a TRP channel.

Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

Method for the treatment of metabolic disorders

Methods for the treatment of metabolic disorders such as diabetes

Growing community of inventors

Potomac, MD, United States of America

Reid W Von Borstel